Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLVS 18.95 +0.51(2.77%)
Will CLVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLVS
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
Bet on 5 Top Stocks With Rising P/E
CLVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why